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Abstract 
Objective: Previously, we suggested that oxaliplatin (L-OHP)-related grade 3/4 hypersensi-
tivity reactions occurred immediately after the initiation, but grade 1/2 reactions did not. This 
study was conducted to clarify the risk factors for L-OHP-related hypersensitivity reactions. 
Methods: Clinical data from 108 Japanese patients with colorectal cancer were analyzed, 
who were treated with L-OHP-containing regimens, FOLFOX4 and/or mFOLFOX6. The risk 
factors  examined  included  demographic  data,  preexisting  allergies,  laboratory  test  data, 
treatment regimen, treatment line of therapy, pretreatment with steroids, total number of 
cycles and cumulative amount of L-OHP. 
Results: The incidence of grade 1/2 and grade 3/4 hypersensitivity reactions were found at 
13.0%  (14/108)  and  9.3%  (10/108),  respectively.  Female  (P=0.037),  preexisting  allergies 
(P=0.004) and lower level of lactate dehydrogenase (P=0.003) were risk factors for grade 1/2 
hypersensitivity reactions, and higher neutrophil count (P=0.043) and lower monocyte count 
(P=0.007) were for grade 3/4 reactions. Total number of cycles were larger in the patients 
with grade 3/4 reactions than those without reactions (P=0.049).  
Conclusions: Further extensive examination with a large number of patients is needed to 
establish a patient management strategy. 
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Introduction 
The treatment of metastatic colorectal cancer has 
progressed significantly over the past 20 years. In the 
early  1990s,  repetitive  injections  of  a  bolus  of 
5-fluorouracil  (5-FU)  and  leucovorin  (LV)  were  the 
standard  treatment,  preferably  with  the  RPMI  regi-
men [1] or Mayo Clinic regimen [2]. In the late 1990s, 
clinical outcome was improved with the continuous 




of a bolus injection of 5-FU and infusion of 5-FU/LV 
resulted  in  a  median  survival  time  (MST)  of  14.7 
months in first-line therapy [3,4]. Treatment has since 
progressed remarkably with the development of the 
anticancer drugs irinotecan (CPT-11) and oxaliplatin 
(L-OHP).  Although  only  a  slight  improvement  in 
clinical outcome was obtained with a combination of 
bolus 5-FU/LV and CPT-11, known as the IFL regi-
men [5], the FOLFIRI regimen consisting of a bolus 
injection  of  5-FU,  CPT-11  and  infusion  of  5-FU/LV 
has increased MST to 17.4 months [6,7]. The simulta-
neously developed FOLFOX regimen consisting of a 
bolus  injection  of  5-FU,  L-OHP  and  infusion  of 
5-FU/LV was also promising, with a MST of 16.2-19.5 
months  [4,7,8].  Currently,  the  FOLFIRI  or  FOLFOX 
regimen, with or without a targeted monoclonal an-
tibody,  is  the  standard  treatment  [9-12],  and  future 
improvements will likely require the incorporation of 
or substitution with a novel anticancer drug, person-
alization based on genetic profiling, or pharmacoki-
netically-guided administration.  
 Hypersensitivity reactions are a well-established 
complication  of  the  platinum  agents,  cisplatin  and 
carboplatin [13-16]. L-OHP, a third-generation plati-
num agent, has been increasingly recognized to cause 
hypersensitivity reactions, but the incidence still var-
ies in reports [17-23], and little information is availa-
ble  for  the  risk  factors  and  therefore  their  manage-
ment, especially in severe cases. Previously, we sug-
gested that grade 3/4 hypersensitivity  reactions oc-
curred  immediately  after  the  initiation,  but  in  con-
trast, grade 1/2 reactions did not [24]. This multicen-
ter retrospective study was conducted to clarify the 
risk factors for L-OHP-related hypersensitivity reac-
tions.  Clinical  data  from  patients  who  experienced 
hypersensitivity  reactions  were  compared  to  those 
from patients who did not. The risk factors examined 
included  demographic  data,  preexisting  allergies, 
laboratory test data, treatment regimen, treatment line 
of therapy, pretreatment with steroids, total number 
of cycles and cumulative amount of L-OHP. 
Patients and Methods 
Eligibility 
All  patients  were  treated  with  the  FOLFOX4 
and/or  mFOLFOX6  regimens  at  either  of  Labor 
Health and Welfare Organization Kobe Rosai Hospi-
tal,  National  Hospital  Organization  Kobe  Medical 
Center,  Kobe  University  Hospital,  Kobe  Red  Cross 
Hospital, and Shinko Hospital, Japan, from April 2005 
to March 2009. All patients had histologically or cy-
tologically  confirmed  advanced  or  metastatic  colo-
rectal adenocarcinoma. Patients had received no prior 
chemotherapy or only one regimen with a washout 
period of more than 4 weeks after the final day of the 
previous  treatment.  Adjuvant  chemotherapy  per-
formed  more  than  6  months  previously  was  not 
counted as previous treatment. Further eligibility cri-
teria included: 1) age of 20-75 years; 2) Eastern Coop-
erative Oncology Group (ECOG) performance status 
of 0 or 1; 3) life expectancy of 3 months or more; 4) 
adequate  hematological  (leukocyte  count: 
4,000/mm3-12,000/mm3,  neutrophil  count: 
2,000/mm3 or more, platelets: 100,000/mm3 or more), 
hepatic (transaminases: 2.5 times or less of the upper 
limit  of  normal,  total  bilirubin:  2.0  mg/dL  or  less),  
and renal (serum creatinine: less than the upper limit 
of normal) function; and 5) ability to take oral medi-
cation.  Depending  on the  clinical  situation,  patients 
who  did  not  meet  the  criteria  can  be  treated  with 
L-OHP  under  the  careful  supervision  of  medical 
doctors.  Patients  were  excluded,  if  they  had  either 
brain metastases, a history of other neoplasms (except 
for cured nonmelanoma skin carcinoma or cured car-
cinoma in situ), a history of severe drug allergies, in-
terstitial  pneumonitis  or  pulmonary  fibrosis,  severe 
pleural effusion or ascites, active infection, bowel ob-
struction, diarrhea, and serious uncontrolled comor-
bidity  or  medical  conditions.  Pregnant  or  lactating 
women or women not using an effective contracep-
tion were also excluded. This retrospective study was 
approved by institutional review boards of each of the 
5 hospitals. 
Data Analysis 
Hypersensitivity  reactions  were  assessed  and 
classified according to the National Cancer Institute 
Common  Criteria  (NCI-CTCAE  v3.0).  Clinical  data 
were  compared  between  the  patients  who  experi-
enced hypersensitivity reactions and those who did 
not. The risk factors examined included gender, age, 
height,  weight,  performance  status,  and  preexisting 
allergies (allergy for specific food or drug, pollinosis 
or allergic rhinitis). The effects of laboratory test data 
on one day before or on the day of the start of therapy 
were also analyzed, including erythrocyte count, he-
moglobin,  hematocrit,  leukocyte  count,  neutrophil 
count, lymphocyte count, eosinophil count, basophil 
count,  monocyte  count,  platelet  count,  aspartate 
aminotransferase  (AST),  alanine  aminotransferase 
(ALT), gamma-glutamyl transpeptidase (γ-GTP), total 
bilirubin (T-Bil), alkaline phosphatase (ALP), lactate 
dehydrogenase  (LDH),  blood  urea  nitrogen  (BUN), 
serum  creatinine  (Scr),  carcinoembryonic  antigen 
(CEA) and CA19-9 antigen (CA19-9). Treatment reg-
imen,  treatment  line  of  therapy,  pretreatment  with 




amount  of  L-OHP  were  also  examined  in  terms  of 
susceptibility to hypersensitivity reactions. 
Statistical Analysis 
All values reported are the mean±standard de-
viation  (SD).  The  unpaired  Student’s t-test/Welch’s 
test  or  Mann-Whitney’s  U  test  was  used  for 
two-group comparisons of the values. Fisher’s exact 
test was used for the analysis of contingency tables. P 
values of less than 0.05 were considered to be signifi-
cant.  
Results 
Demographics  and  the  data  on  laboratory  test 
and  chemotherapy  in  108  patients  who  received 
L-OHP are summarized in Table 1. Average values of 
age, height and total body weight of 108 patients were 
64.5±9.8  years, 160.6±9.0  cm  and  57.1±9.7  kg,  re-
spectively.  Ten  of  108  patients  (9.3%)  experienced 
grade 3/4 hypersensitivity reactions, whereas grade 
1/2 events occurred in 14 patients (13.0%). 
There was no statistical difference of age, height, 
weight and performance status between the patients 
with  no  and  grade  1/2  hypersensitivity  reactions. 
Compared with men, woman had a higher suscepti-
bility  to  grade  1/2  hypersensitivity  reactions 
(p=0.037). Eight of 14 patients (57.1%) with grade 1/2 
hypersensitivity  reactions  had  preexisting  allergies, 
but only 17.9% (15/84) of patients without reactions 
(p  =  0.004).  Laboratory  test  data  on  hematological, 
hepatic and renal functions were independent of, but 
lower LDH level was risk factor for grade 1/2 hyper-
sensitivity  reactions  (P=0.003).  No  meaningful  dif-
ferences were observed between the patients with no 
and  grade  1/2  hypersensitivity  reactions,  with  re-
gards to treatment regimen, treatment line of therapy, 
pretreatment with steroids, total number of cycles and 
cumulative amount of L-OHP. 
 








Grade 3/4  
N=10 
Patients       
 Male/female  56/28  5/9 *  6/4 
 Age, year  65.2±9.2 [36-83 ]  60.1±12.2 [ 36-72 ]  65.5±10.6 [ 46-76 ] 
 Height, cm  160.9±9.0 [132.0-179.2]  158.0±9.7 [143.8-168.9]  162.1±8.4 [149.5-174.0] 
 Weight, kg  56.4±9.8 [36.0-80.0]  59.5±9.4 [44.0-76.0]  59.9±8.7 [50.0-75.5] 
 Performance status, 0/1/2/3  70/6/6/2  12/1/1/0  9/1/0/0 
 Allergic history, yes/no  15/69  8/6 *  2/8 
Laboratory test       
 Erythrocyte count, ×104 /mm3  384±57 [225-489]  389±64 [287-491]  424±57 [359-520] 
 Leukocyte count, /mm3  6848±3560 [3100-30500]  6086±1964 [3370-11300]  7515±2509 [4600-14010] 
 Neutrophil count, /mm3  4639±3500 [839-28975]  3744±1877 [1618-8780]  5938±2929 [3340-12889] * 
 Lymphocyte count, /mm3  1461±621 [224-3054]  1600±532 [1170-2503]  1357±412 [773-1864] 
 Monocyte count %  7.6±2.9 [1.0-19.8]  7.8±1.9 [4.7-11.0]  5.2±1.8 [2.0-7.9] * 
 Platelet count, ×104 /mm3  28.2±9.8 [13.2-53.3]  24.1±9.1 [10.9-42.9]  31.4±15.1 [14.8-57.0] 
 Lactate dehydrogenase, IU/L  298±230 [8-1248]  171±29 [135-210] *  451±297 [146-985] 
Chemotherapy       
 FOLFOX4/mFOLFOX6/both  41/40/3  7/7/0  6/3/1 
 Line of therapy, 1st/2nd or more  28/56  4/10  4/6 
 Pretreatment with steroids, yes/no  81/3  12/2  10/0 
 Total cycle number of therapy  6.6±4.0 [1-19]  8.4±4.4 [2-17]  9.3±3.9 [ 5-16 ] * 
 Cumulative amount of L-OHP, mg/m2    521.4±329.3 [ 40.8-1374.3 ]  675.8±352.2 [ 156.3-1306.1 ] 
 
726.7±316.3 [ 406.3-1342.3 ] 
 
The values are the mean±SD with the range in parentheses.  
* P < 0.05, compared with the patients without hypersensitivity reactions 
 




As for grade 3/4 reactions, no difference of de-
mographic data was found, when compared with the 
patients with no reactions. Preexisting allergies were 
also not predictive of grade 3/4 hypersensitivity re-
actions. No association was found for the laboratory 
test data on hepatic and renal functions, but higher 
neutrophil count (P=0.043) and lower monocyte count 
(P=0.007)  were  risk  factors  for  grade  3/4  reactions. 
Treatment-related  conditions  were  independent  of 
grade 3/4 hypersensitivity reactions, except for total 
cycle number of therapy (p=0.049). 
Discussion 
Hypersensitivity  reactions  to  the  platinum 
agents cisplatin and carboplatin are well documented 
[13-16]. For cisplatin, the incidence of hypersensitivity 
reactions have been reported as 2-5% when adminis-
tered  as  a  single  agent  and  5-10%  when  combined 
with other agents [14]. Carboplatin induces reactions 
with  an  incidence  of  12-27%  [13,16].  With  the  in-
creasing  use  of  L-OHP  in  clinical  practice, 
L-OHP-induced hypersensitivity reactions have been 
encountered frequently, and reportedly, the incidence 
ranged from 3.6% to 18.9% in total, but serious reac-
tions hardly happened in Western countries [17-22]. 
In  a  randomized  phase  III  trial,  the  MOSAIC  trial, 
10.3% of the 1108 patients experienced hypersensitiv-
ity  reactions,  and  2.3%  and  0.6%  had  grade  3  and 
grade 4 reactions, respectively [17]. In this study, we 
found  that  22.2%  of  Japanese  patients  who  were 
treated with L-OHP-containing regimens experienced 
hypersensitivity reactions, and grade 3/4 events oc-
curred in 9.3% of patients. This incidence is relatively 
high than those in the reports, suggesting a racial ef-
fect. However, more recently, a report from Japanese 
affiliation indicated that 17.0% of 125 patients expe-
rienced hypersensitivity reactions, with grade 3/4 at 
4.0% [23]. These values are still higher than those in 
the MOSAIC trial, but lower than those in our study. 
Thus,  clinical  factors  might  affect  the  incidence,  in-
cluding the pre-dosing of antihistamines or steroids. 
Only  a  few  investigations  have  attempted  to 
identify potential risk factors for hypersensitivity re-
actions to L-OHP. Lee et al. analyzed the possible as-
sociation  between  L-OHP-induced  anaphylaxis  and 
metastases, but no significant association was identi-
fied [25]. Kim et al. suggested that a higher incidence 
was found in younger patients, female patients, and 
patients with salvage therapy [26], whereas Shibata et 
al. reported no correlation with gender and history of 
allergy  [23].  Here,  it  was  suggested  that  female 
(P=0.037),  preexisting  allergies  (P=0.004)  and  lower 
LDH level (P=0.003) were risk factors for grade 1/2 
hypersensitivity  reactions,  and  higher  neutrophil 
count (P=0.043) and lower monocyte count (P=0.007) 
were for grade 3/4 reactions (Table 1). The reasons for 
increase of risk amongst female are unknown, but this 
finding implicates a possible role of hormonal influ-
ences  [26].  A  history  of  allergy  for  specific  food  or 
drug, pollinosis  or allergic rhinitis were handled as 
preexisting  allergies,  and  the  common  mechanisms 
might exist for these allergies and grade 1/2 hyper-
sensitivity reactions. LDH is found in the liver, kid-
neys,  striated  muscle,  skin  and  heart  muscle,  and 
therefore is widely used to diagnose the condition of 
patients  with  lung, heart, blood and  malignant dis-
eases. The patients in this study were all with colo-
rectal  adenocarcinoma  and  most  of  them  showed 
higher LDH level than normal levels. Here, the LDH 
level was within the normal range in the patients with 
grade  1/2  hypersensitivity  reactions  (Table  1),  alt-
hough  the  reasons  are  not  clear.  Neutrophils  and 
monocyte/macrophages  are  phagocytic  cells,  which 
play an important role in host defense, but are also 
inflammatory cells, that can mediate tissue damage. 
Both cells are essential for the innate immune system, 
but recent researches suggest that the recognition and 
subsequent  engulfment  of  apoptotic  neutrophils  by 
macrophages is involved in the resolution of inflam-
mation [27, 28], and therefore the stage of inflamma-
tion in the patients with higher neutrophil count and 
lower  monocyte  count  is  supposed  to  be  different 
from others. Total cycle number of therapy was larger 
in the  patients  with  grade 3/4 reactions than those 
without reactions (P=0.049), and thus extensive repe-
tition of therapy might result in grade 3/4 reactions 
(Table 1). Further extensive examination with a large 
number of patients is needed to identify the risk fac-
tors, and to establish a patient management strategy. 
Although  hypersensitivity  reactions  are  a 
well-established complication of the platinum agents 
[13-23], their exact mechanism remains unclear. The 
agents are thought to induce a type I response medi-
ated by IgE, followed by the release of histamine and 
cytokines, since reactions usually occur after multiple 
infusions [29-32]. Recent studies have suggested the 
involvement of a type IV reaction, i.e., T-cell-mediated 
production of cytokines, such as tumor necrosis fac-
tor-alpha  and  interleukin-6,  especially  for  cisplatin 
and carboplatin [29-32]. As far as L-OHP is concerned, 
most reactions are thought to be of type I, but reports 
of hemolysis and thrombocytopenia suggest a type II 
reaction,  and  chronic  urticaria,  joint  pain  and  pro-
teinuria can be attributed to a type III reaction [29-32]. 
In our previous report, we suggested that grade 3/4 
hypersensitivity reactions occurred immediately after 
the initiation, but in contrast, grade 1/2 reactions did 




grade 3/4 reactions were not in accordance with those 
for grade 3/4 reactions. These findings might suggest 
that the different mechanisms exist to separate them. 
Delayed hypersensitivity reactions are generally less 
severe than acute reactions, and might include red-
ness of the palms and torso, and pruritus [30]. Strate-
gies  to  manage  delayed  hypersensitivity  reactions 
include  desensitization  approaches  such  as  use  of 
steroids, antihistamines, and prolongation of infusion 
time, but L-OHP discontinuation is recommended for 
acute anaphylactic reaction [30]. 
In  conclusion,  this  multicenter  retrospective 
study  was  conducted  to  clarify  the  risk  factors  for 
L-OHP-related  hypersensitivity  reactions.  Clinical 
data from the patients who experienced hypersensi-
tivity reactions were compared to those from the pa-
tients who did not. The incidence of grade 1/2 and 
grade  3/4  hypersensitivity  reactions  were  found  at 
13.0% and 9.3%, respectively. Female, preexisting al-
lergies  and  lower  LDH  level  were  risk  factors  for 
grade 1/2 hypersensitivity reactions, and higher neu-
trophil  count  and  lower  monocyte  count  were  for 
grade 3/4 reactions. Extensive repetition of therapy 
resulted  in  grade  3/4  reactions.  Further  extensive 
examination with a large number of patients is need-
ed to establish a patient management strategy. 
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